The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Oct 2015 New trial record